eli lilly - Search News

Eli Lilly shares drop

Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.

Yahoo · 1d

Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.

Wall Street Journal on MSN · 3d

Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Crohn's disease, Lilly

The Wall Street Journal on MSN · 19h

Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s disease, an inflammatory bowel disease that causes chronic abdominal pain.

Reuters on MSN · 15h

US FDA approves expanded use of Lilly's bowel disease drug

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease (IBD). The drug, branded as Omvoh,

Seeking Alpha on MSN · 19h

Lilly gets FDA approval for Omvoh for Crohn's disease

Eli Lilly (NYSE:LLY) has received FDA approval for its drug Omvoh, also known as mirikizumab-mrkz, for the treatment of moderately to severely active Crohn's disease in adults. The drug was previously approved in 2023 for the treatment of moderately to severely active ulcerative colitis in adults.

Zepbound, Lilly and Mounjaro

STAT · 19h

Eli Lilly is considering offering more Zepbound doses in vials at lower cost

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning to compounding pharmacies that make cheaper copies of Zepbound, since the branded treatment has been too costly and, up until recently, has been in shortage.

Barron's on MSN · 1d

Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those results unsettled investors, setting off a three-week sello

Zacks.com on MSN · 22h

NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down

Has Eli Lilly Stock Peaked?

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

Eli Lilly price target lowered to $970 from $1,050 at Berenberg

Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.

21h

Eli Lilly: Big 2025 Ahead, But Execution Risks Exist

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

FiercePharma1d

JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Insider Monkey2d

Why Eli Lilly (LLY) Stock Is Declining Today

The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced lower-than-expected ...

Eli Lilly's obesity drug gets Medicare coverage for sleep apnea

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

19h

After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Eli Lilly shares drop

Crohn's disease, Lilly

Zepbound, Lilly and Mounjaro

Related topics